Investigation of new biomarkers of treatment response in glioblastoma multiforme (an aggressive brain cancer)

2020

Every year an estimated 290 malignant tumours of the brain are diagnosed in Ireland.  Glioblastoma multiforme is a very aggressive form of brain cancer.
Only 2%, or 1 in 50 people who get this cancer survive more than 3 years after their diagnosis.  These people who survive are called ‘extreme responders’ i.e. they have had an excellent response to the chemotherapy used as the standard of care for this cancer.
The aim of this study is to investigate the role of 324 cancer-related genes among patients with Glioblastoma multiforme, who are extreme responders to chemotherapy and those who are not.
Through this research, the team hopes to improve the understanding of this cancer and also to identify potentially new treatment opportunities for this cancer.

More information on Brain cancers in Ireland can be found at the following link;
https://www.ncri.ie/news/article/trends-brain-cancer-ireland-our-latest-report-published

Back
Start year:
2020
Principal Investigator:
Dr Richard Bambury
Host Institution:
Cork University Hospital
Cancer type:
Glioblastoma multiforme (an aggressive brain cancer)
Linked Breakthrough Research Priorities:
1, 5

View More